Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem Autologous SCT for Hodgkin's Lymphoma
NCT00265889Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2002
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan, carmustine, etoposide, cyclophosphamide in Hodgkin lymphoma (HL), sponsored by Case Comprehensive Cancer Center. Started Feb 2002; status: completed.
02
Drugs
melphalancarmustineetoposidecyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00265889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265889.